Acute procedural complications and in-hospital events after percutaneous coronary interventions - Eptifibatide versus Abciximab

Cardiovascular Radiation Medicine

Volumn 4, Issue 1, 2003, Pages 12-17

  Ajani, Andrew E ^a   Waksman, Ron ^a   Gruberg, Luis ^a   Sharma, Arvind K ^a   Lew, Robert ^a   Pinnow, Ellen ^a   Canos, Daniel A ^a   Cheneau, Edouard ^a   Castagna, Marco ^a   Satler, Lowell ^a   Pichard, Augusto ^a   Kent, Kenneth M ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Abciximab; Eptifibatide; Percutaneous coronary interventions

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; BOLUS INJECTION; COMPLICATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DEMOGRAPHY; DRUG INFUSION; FEMALE; HEART DEATH; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION;

EID: 10744220235     PISSN: 15221865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1522-1865(03)00120-3     Document Type: Article

References (25)

1. Tcheng J.E. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. Am J Cardiol. 83:1999;7E-11E.
2. Lefkovits J., Plow E., Topol E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
3. Madan M., Berkowitz S., Tcheng J. Glycoprotein IIb/IIIa integrin blockade. Circulation. 98:1998;2629-2635.
4. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med. 330:1994;956-961.
5. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators. N Engl J Med. 336:1997;1689-1696.
6. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet. 352:1998;87-92.
7. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 349:1997;1429-1435.
8. Brener SJ, Barr LA, Burchenal JE, Wolski KE, Effron MB, Topol EJ. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro and primary PTCA organization and randomized trial. Am J Cardiol 1999;84:728-30, A8.
9. Berkowitz S.D., Harrington R.A., Rund M.M., Tcheng J.E. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation. 95:1997;809-813.
10. Dasgupta H., Blankenship J.C., Wood G.C., Frey C.M., Demko S.L., Mcnapace F.J. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 140:2000;206-211.
11. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet. 349:1997;1422-1428.
12. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 339:1998;436-443.
13. Kereiakes D.J., Broderick T.M., Roth E.M., Whang D., Shimshak T., Runyon J.P., Hattemer C., Schneider J., Lacock P., Mueller M., Abbottsmith C.W. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol. 84:1999;391-395.
14. Tcheng J.E. The enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy (ESPRIT) trial. Am Heart J. 140(6):2000;834-839.
15. Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999;138:4(2):287-96.
16. Bishara A.I., Hagmeyer K.O. Acute profound thrombocytopenia following abciximab therapy. Ann Pharmacother. 34:2000;924-930.
17. Lincoff A.M., Califf R.M., Topol E.J. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol. 35:2000;1103-1115.
18. Tcheng J.E., Ellis S.G., George B.S., Kcreiakes D.J., Kleiman N.S., Talley J.D., Wang A.L., Weisman H.F., Califf R.M., Topol E.J. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
19. Tcheng J.E. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 139:2000;S38-S45.
20. Le Breton H., Plow E.F., Topol E.J. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 28:1996;1643-1651.
21. Booth J.E., Patel V.B., Balog C., Miller D.P., Juran N.B., LeNarz L., Lincoff M. Is bleeding risk increased in patients undergoing urgent coronary bypass surgery following abciximab? Circulation. 98(Suppl I):1998;845.
22. Topol E.J. TARGET: do tirofiban and reopro give similar efficacy trial? Circulation. 102:2000;2672. abstract.
23. Tcheng J., Keriakes D. Safety of abciximab retreatment-final clinical report of the reopro readministration registry (R3). Circulation. 98(Suppl I):1998;17. abstract.
24. Topol E.J., Mark D.B., Lincoff A.M., Cohen E., Burton J., Kleiman N., Talley D., Sapp S., Booth J., Cabot C.F., Anderson K.M., Califf R.M. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet. 354:1999;2019-2024.
25. Cox J., Naylor C.D. The Canadian Cardiovascular Society grading scale for angina pectoris: is it time for refinements? Ann Intern Med. 117:1992;677-683.